Search results
Showing 1 to 15 of 18 results for gout
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
Awaiting development Reference number: GID-QS10100 Expected publication date: TBC
Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain (HTG436)
Evidence-based recommendations on minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain in adults. This involves fixing the sacrum to the ilium using 2 or 3 metal implants.
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
diabetes, these medicines may affect your blood sugar levels. If you have gout, then these medicines can make it worse. ACE inhibitor...
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
This quality standard covers diagnosing, assessing and managing osteoarthritis in adults aged over 16. It includes treatment and support, and referral for joint surgery. It describes high-quality care in priority areas for improvement.
View quality statements for QS87Show all sections
Sections for QS87
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Assessment at diagnosis
- Quality statement 3: Information and support
- Quality statement 4: Therapeutic exercise
- Quality statement 5: Weight loss
- Quality statement 6: Follow-up
- Quality statement 7: Core treatments before referral for consideration of joint surgery
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
Febuxostat for the management of hyperuricaemia in people with gout (TA164)
This guidance has been updated and replaced by NICE guideline NG219.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)
We have withdrawn this guidance. Grünenthal has stopped marketing Lesinurad (Zurampic) for commercial reasons and its marketing authorisation has been withdrawn.
Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)
The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.